Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier



    David Yeung 3 Susan Branford                    

    Session 2: CML Management, Practicalities
    Chair: Dr David Yeung

    • Managing TKI toxicities
      (Dr Naranie Shanmuganathan)
    • Allograft - still a role in CML?
      (Dr David Yeung)
    • Molecular monitoring
      (A/Prof Susan Branford)






    Managing TKI toxicities
    Dr Naranie Shanmunagathan, Royal Adelaide Hospital / SA Pathology / SAHMRI

    • Imatinib including bone health
    • Nilotinib including; 5 year follow-up of ENESTnd, hypercholeraemia and hyperglcaemia and prolonged QTc
    • Dasatinib including; 5-year follow-up of DASISION, potential strategy to reduce pleural effusions and management of DAS associated pulmonary toxicity
    • Bosutinib
    • Ponatinib
    • Cardiovascular toxicity and TKI's
    • Pancreatitis
    • Managing haematological toxicity
    • Summary


    David Yeung 3  

    Allograft - still a role in CML?
    Dr David Yeung - SAHMRI / Royal Adelaide Hospital

    • Patient case
    • Allogeneic stem cell transplantation: the most successul immunotherapy in CML
    • German IIIA study
    • Impact of drug development on the use of stem cell transplantation
    • Strategies to reduce the risk of disease relapse in patients allografted in CML
    • EBMT score for allo SCT in CML
    • Graft source: BM better than PDSC in CP-CML
    • Long-term follow-up after transplant for CML
    • Summary

    Susan Branford



    Monitoring TFR - Challenges
    A/Prof. Susan Branford, SA Pathology / Universities of Adelaide and South Australia

    • Gold standards of monitoring in CML
    • Molecular monitoring for best patient outcomes
    • Milestone molecular responses in the first 12 months
    • Long-term molecular monitoring is recommended for prediction of resistance
    • IM resistant BCR-ABL1 kinase domain mutations
    • Long-term molecular monitoring of responsing patients is important to monitor adherence
    • Regular molecular monitoring is recommended for optimal disease management
    • Summary